2023 international evidence-based guideline pcos glp-1 receptor agonist Recommendations from the for the Assessment and Management of Polycystic Ovary Syndrome† Is there evidence that micro‑dosing

Omega 3 / Lutena / L-Carnitina / Vitaminas / Minerales

Strategic Investments by Pharmaceutical Leaders Are Expanding Therapeutic Innovation and Accessibility Global pharmaceutical companies are committing significant resources to developing new GLP-1 receptor agonists with improved efficacy and convenience

Insurance companies determine coverage based on whether a treatment is considered medically necessary

45 Products that are a combination of a DPP-4 inhibitor and an SGLT2 inhibitor (sitagliptin/ertugliflozin, saxagliptin/dapagliflozin, and linagliptin/empagliflozin) may be used to further lower A1C and provide increased CV benefit in patients who are not meeting A1C goals on dual therapy

Challenges to global standardization of outcome measures